Molecular Epidemiology, Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands; Neonatology, Willem-Alexander Children's Hospital, Department of Pediatrics, Leiden University Medical Center, Leiden, The Netherlands.
Molecular Epidemiology, Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands.
Cytotherapy. 2023 Oct;25(10):1057-1068. doi: 10.1016/j.jcyt.2023.07.004. Epub 2023 Jul 28.
Human umbilical cord-derived mesenchymal stromal cells (hUC-MSCs) are increasingly used in research and therapy. To obtain hUC-MSCs, a diversity of isolation and expansion methods are applied. Here, we report on a robust and standardized method for hUC-MSC isolation and expansion.
Using 90 hUC donors, we compared and optimized critical variables during each phase of the multi-step procedure involving UC collection, processing, MSC isolation, expansion and characterization. Furthermore, we assessed the effect of donor-to-donor variability regarding UC morphology and donor attributes on hUC-MSC characteristics.
We demonstrated robustness of our method across 90 UC donors at each step of the procedure. With our method, UCs can be collected up to 6 h after birth, and UC-processing can be initiated up to 48 h after collection without impacting on hUC-MSC characteristics. The removal of blood vessels before explant cultures improved hUC-MSC purity. Expansion in Minimum essential medium α supplemented with human platelet lysate increased reproducibility of the expansion rate and MSC characteristics as compared with Dulbecco's Modified Eagle's Medium supplemented with fetal bovine serum. The isolated hUC-MSCs showed a purity of ∼98.9%, a viability of >97% and a high proliferative capacity. Trilineage differentiation capacity of hUC-MSCs was reduced as compared with bone marrow-derived MSCs. Functional assays indicated that the hUC-MSCs were able to inhibit T-cell proliferation demonstrating their immune-modulatory capacity.
We present a robust and standardized method to isolate and expand hUC-MSCs, minimizing technical variability and thereby lay a foundation to advance reliability and comparability of results obtained from different donors and different studies.
人脐带间充质干细胞(hUC-MSCs)越来越多地用于研究和治疗。为了获得 hUC-MSCs,应用了多种分离和扩增方法。在这里,我们报告了一种强大且标准化的 hUC-MSC 分离和扩增方法。
使用 90 位 hUC 供体,我们比较和优化了多步程序的每个阶段的关键变量,该程序涉及 UC 收集、处理、MSC 分离、扩增和特征鉴定。此外,我们评估了 UC 形态和供体属性对 hUC-MSC 特征的 donor-to-donor 变异性的影响。
我们证明了我们的方法在程序的每个步骤中都具有 90 个 UC 供体的稳健性。使用我们的方法,可以在出生后 6 小时内收集 UC,并在收集后 48 小时内开始 UC 处理,而不会影响 hUC-MSC 特征。在进行组织块培养之前去除血管可以提高 hUC-MSC 的纯度。在补充有人类血小板裂解物的基础培养基α中进行扩增,与在补充有胎牛血清的 Dulbecco 改良 Eagle 培养基中相比,提高了扩增率和 MSC 特征的可重复性。分离的 hUC-MSCs 的纯度约为 98.9%,活力>97%,增殖能力高。与骨髓间充质干细胞相比,hUC-MSCs 的三系分化能力降低。功能测定表明,hUC-MSCs 能够抑制 T 细胞增殖,证明其具有免疫调节能力。
我们提出了一种强大且标准化的方法来分离和扩增 hUC-MSCs,最大限度地减少技术变异性,从而为不同供体和不同研究中获得的结果的可靠性和可比性奠定基础。